Shield Therapeutics plc

DB:1JS Stock Report

Market Cap: €23.3m

Shield Therapeutics Management

Management criteria checks 3/4

Shield Therapeutics' CEO is Anders Lundstrom, appointed in Jul 2024, has a tenure of less than a year. directly owns 0.001% of the company’s shares, worth €298.23. The average tenure of the management team and the board of directors is 1.8 years and 4.1 years respectively.

Key information

Anders Lundstrom

Chief executive officer

US$53.5k

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership0.001%
Management average tenure1.8yrs
Board average tenure4.1yrs

Recent management updates

Recent updates

CEO

Anders Lundstrom (62 yo)

less than a year

Tenure

US$53,542

Compensation

Mr. Anders Lundstrom has been Interim Chief Executive Officer of Shield Therapeutics plc since July 24, 2024 and serves as its Independent Non-Executive Director since May 10, 2021. Mr. Lundstrom joined Or...

Leadership Team

NamePositionTenureCompensationOwnership
Anders Lundstrom
Interim CEO & Independent Non-Executive Directorless than a yearUS$53.54k0.0013%
€ 298.2
Christian Schweiger
Co-Founder & Non Executive Director17yrsUS$47.17k1.49%
€ 347.1k
Santosh Shanbhag
Chief Financial Officerless than a yearno datano data
Lucy Huntington-Bailey
General Counsel & Company Secretary7.3yrsno datano data
Suzanne Wood
Group HR Directorno datano datano data
Carol Akinola
Head of Pharmacovigilance & Medical Informationno datano datano data
Andrew Hurley
Chief Commercial Officer1.8yrsno datano data
Kate Armanetti
Senior Director of People & Cultureno datano datano data

1.8yrs

Average Tenure

56.5yo

Average Age

Experienced Management: 1JS's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Anders Lundstrom
Interim CEO & Independent Non-Executive Director3.7yrsUS$53.54k0.0013%
€ 298.2
Christian Schweiger
Co-Founder & Non Executive Director4.6yrsUS$47.17k1.49%
€ 347.1k
Hans Hasler
Independent Non Executive Chairman6.5yrsUS$119.83k0.70%
€ 163.9k
Rudolf Widmann
Non-Executive Directorless than a yearno datano data
Peter Llewellyn-Davies
Independent Non-Executive Director8.9yrsUS$76.49k0.023%
€ 5.3k
Christoph Gasche
Notable Scientific Advisory Boardno datano datano data
Maria Lacerca-Allen
Independent Non-Executive Director3.7yrsUS$47.17k0.035%
€ 8.1k
Geoffrey Block
Notable Scientific Advisory Boardno datano datano data
Michael Stockham
Notable Scientific Advisory Boardno datano datano data
Jonathon Powell
Notable Scientific Advisory Boardno datano datano data

4.1yrs

Average Tenure

60yo

Average Age

Experienced Board: 1JS's board of directors are considered experienced (4.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 07:55
End of Day Share Price 2025/01/10 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shield Therapeutics plc is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Howard MillerCanaccord Genuity
Stuart HarrisCavendish
Alexander PyeCavendish